이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Fusion Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

Fusion Pharmaceuticals의 수입은 연평균 -18%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 15.5%의 비율로 증가했습니다. 매출은 연평균 31%의 비율로 증가해 왔습니다.

주요 정보

-18.0%

수익 성장률

64.0%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	31.0%
자기자본 수익률	-43.1%
순이익	-5,111.6%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook

Mar 03

Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Jan 30

Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors

Sep 16

Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment

Aug 29

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Aug 10

Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M

Aug 09

Fusion Pharma wins FDA nod to start trials for solid tumor candidate

Jun 23

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Jan 16

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Aug 28

Fusion Pharma trades higher on early-stage data for cancer therapy

Jun 14

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

Apr 05

How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Mar 01

Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

Jan 25

Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

Dec 21

Fusion Pharmaceuticals EPS misses by $0.04

Nov 10

Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer

Nov 02

수익 및 비용 분석

Fusion Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGS:FUSN 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	2	-104	37	0
31 Dec 23	2	-95	31	0
30 Sep 23	2	-91	31	0
30 Jun 23	0	-98	31	0
31 Mar 23	1	-92	31	0
31 Dec 22	1	-88	31	0
30 Sep 22	2	-80	30	0
30 Jun 22	2	-76	30	0
31 Mar 22	2	-83	29	0
31 Dec 21	1	-81	27	0
30 Sep 21	1	-77	27	0
30 Jun 21	1	-68	26	0
31 Mar 21	0	-86	23	-4
31 Dec 20	0	-80	21	0
30 Sep 20	0	-75	17	3
30 Jun 20	0	-65	13	6
31 Mar 20	0	-24	11	12
31 Dec 19	0	-16	8	11
31 Dec 18	0	-12	3	7

양질의 수익: FUSN 은(는) 현재 수익성이 없습니다.

이익 마진 증가: FUSN 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: FUSN 은(는) 수익성이 없으며 지난 5년 동안 연간 18% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 FUSN 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: FUSN 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: FUSN 현재 수익성이 없기 때문에 마이너스 자본 수익률( -43.12% )을 갖습니다.

Fusion Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings released: US$0.40 loss per share (vs US$0.45 loss in 1Q 2023)

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.55 loss in 3Q 2022)

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Fusion Pharmaceuticals Files Form 15

Fusion Pharmaceuticals Inc.(NasdaqGS:FUSN) dropped from NASDAQ Biotechnology Index

Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

First quarter 2024 earnings released: US$0.40 loss per share (vs US$0.45 loss in 1Q 2023)

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.55 loss in 3Q 2022)

AstraZeneca AB entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.8 billion.

Consensus EPS estimates fall by 11%

AstraZeneca AB entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.8 billion.

AstraZeneca AB entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.8 billion.

AstraZeneca PLC (LSE:AZN) entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.5 billion.

Price target increased by 34% to US$18.80

AstraZeneca PLC (LSE:AZN) entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.5 billion.

Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook

Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Price target increased by 7.5% to US$14.27

Consensus revenue estimates increase by 266%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fusion Pharmaceuticals Inc. Announces Board Changes

Fusion Pharmaceuticals Inc. Announces Presentation of Preclinical Data Supporting FPI-2068, A Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers

Consensus revenue estimates increase by 160%

New minor risk - Share price stability

Consensus revenue estimates increase by 304%

Consensus revenue estimates fall by 91%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fusion Pharmaceuticals Inc. to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R

Consensus revenue estimates increase by 289%

New major risk - Shareholder dilution

Fusion Pharmaceuticals Inc. announced that it expects to receive $20 million in funding from Federated Hermes, Inc.

Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T

Fusion Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2023

Price target decreased to US$13.95

Fusion Pharmaceuticals Appoints Dmitri Bobilev as Chief Medical Officer

Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors

Fusion Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1/2 Study of FPI-1966 in Patients with Advanced Solid Tumors Expressing FGFR3

Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment

Independent Director recently bought US$90k worth of stock

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M

Price target decreased to US$16.14

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1

Fusion Pharma wins FDA nod to start trials for solid tumor candidate

Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434

Fusion Pharmaceuticals Inc. Provides Updates on FPI-1434 and FPI-1966 Clinical Programs

Consensus revenue estimates fall by 84%

Fusion Pharmaceuticals Inc. Announces Executive Changes

Price target decreased to US$18.20

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development

Price target decreased to US$19.00

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Price target decreased to US$21.33

Consensus revenue estimates fall to US$173.7k

Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434

Fusion Pharma trades higher on early-stage data for cancer therapy

Consensus forecasts updated

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

New 90-day low: US$11.25

How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Fusion Pharmaceuticals Appoints Philina Lee to Its Board of Directors

New 90-day low: US$11.26

Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

New 90-day low: US$11.56

Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, A Cancer-Fighting Medical Isotope

Fusion Pharmaceuticals Inc. Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors

Fusion Pharmaceuticals EPS misses by $0.04

New 90-day high: US$13.73

Fusion Pharmaceuticals Inc. Appoints Barbara Duncan as Chairperson of the Board of Directors

Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer

Fusion Pharmaceuticals Appoints Maria Stahl as Chief Legal Officer

New 90-day low: US$12.20